Topic

Articles

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

The company has announced plans to establish a commercial presence in six European countries.

Moderna Plans Expansion in Europe

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

Thermo Fisher Scientific Invests $40 Million to Expand Bioprocessing Manufacturing Site

The commercialization and licensing deal will see Biogen commercialize Xbrane’s Xcimzane, a proposed biosimilar for CIMZIA (certolizumab pegol).

Biogen and Xbrane Ink Agreement for Proposed Biosimilar

ONK will receive non-exclusive rights to Intellia’s proprietary ex-vivo CRISPR/Cas9 technology in the development of five allogeneic NK cell therapies.

Intellia and ONK Therapeutics Enter Gene-Editing Partnership

ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.

ImmunoGen Grants Lilly Exclusive Research, Development, and Commercialization License in $1.7+ Billion ADC Deal

The deal between ProBioGen and AstraZeneca will allow AstraZeneca to use ProBioGen’s GlymaxX technology.

ProBioGen Inks License Agreement Deal with AstraZeneca

Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.

Piramal Pharma Solutions Expands and Upgrades UK Manufacturing Facilities

In an agreement with MaaT Pharma, Skyepharma will build MaaT a dedicated 1500-m² microbiome ecosystem therapies manufacturing site.

Skyepharma and MaaT Ink Manufacturing Agreement

The European Patent Office has granted another patent to Salipro Biotech,  covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

Bio/Pharma Business